Approach to Abnormal Liver Tests in IBD

This IBD clinical care pathway is a tool providing healthcare providers direction on the evaluation of elevated liver enzymes in patients with inflammatory bowel disease.

Download the PDF

Disclaimer: Clinical care pathways are not a substitute for the personalized judgement and care of a trained healthcare professional.

Dr. Aldo J. Montano-Loza (University of Alberta) and Dr. Alex Frolkis (University of Calgary) are the leads for this clinical care pathway, including regular review and maintenance.

Additional resources

For IBD providers

LiverTox - NCBI Bookshelf – NIH. National Institutes of Health (.gov): https://www.ncbi.nlm.nih.gov › books › NBK547852 (Link)
Guidelines on the management of abnormal liver blood tests https://doi.org/10.1136/gutjnl-2017-314924 (Link)
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries: https://pubmed.ncbi.nlm.nih.gov/27995906/ (Link)

Please provide us with feedback!

If you have used this clinical care pathway, please take a moment to fill out this short feedback survey

Quick FactFaits en bref

Canada has among the highest incidence rates of Crohn's and colitis in the world.
1 in 140 Canadians lives with Crohn’s or colitis.
Families new to Canada are developing these diseases for the first time.
Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
People are most commonly diagnosed before age 30.

Inflammatory Bowel Disease Clinical Care Pathways